β-Thalassaemias: Highlights from the European Hematology Association Scientific Working Group (EHA-SWG) Scientific Meeting on Anaemias: Diagnosis and Treatment in the Omics Era

This article comprises a summary of scientific sessions on β-thalassaemia that took place on 2nd–4th February 2017, as part of the European Hematology Association Scientific Working Group meeting: Anaemias: Diagnosis and Treatment in the Omics Era, in Barcelona, Spain

Chairpersons and speakers: Clara Camaschella,1,2 Ali T. Taher,3 Maria-Domenica Cappellini4,5

1. Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy
2. Fondazione Centro San Raffaele, Milan, Italy
3. Division of Haematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
4. Department of Internal Medicine, Foundation Ca’ Granda Ospedale Maggiore Polyclinico (IRCCS), Milan, Italy
5. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

Disclosure: Dr Camaschella has received honorarium for contributions to a steering committee meeting funded by Vifor Pharma. Prof Taher has received honoraria for research support and attending an advisory board funded by Novartis Pharma A/G and has received research support from Celgene. Dr Cappellini has received honoraria for attending advisory boards funded by Novartis Pharma A/G, Sanofi/Genzyme, Celgene, and Vifor.
Acknowledgements: This publication includes summaries of sessions presented by Prof Stefano Rivella, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA and Prof Douglas Higgs, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. Writing assistance was provided by Kate Weatherall, ApotheCom, London, UK.
Support: The publication of this article was funded by Celgene. The views and opinions expressed are those of the authors and not necessarily Celgene.
Citation: EMJ Hematol. 2017;5[1](Suppl 11):2-10.

Download (PDF, 1.97MB)

Comments are closed.